Bio 2006 Analysts Predict Small-Cap Biotechs to Outperform Large-Caps This Year

Samaritan Pharmaceuticals Inc. (AMEX:LIV)

   --  David W. Munno, Merrill Lynch VP of biotechnology, stated,
        "Large-cap biotech firms need some blockbuster products for
        meaningful growth which is more than likely to come from
        small- to mid-sized biotechs."

   --  Vinny Jindal, of Think Equity Partners LLC, stated, "Small-cap
        biotech is going to have a banner year."

   Samaritan Pharmaceuticals Inc., a developer of innovative drugs,
announced today that biotech analysts at Bio 2006 in Chicago, the
industry's largest conference, predicted encouraging trends for
small-caps like Samaritan.
   Dr. Greeson, CEO of Samaritan, stated, "We found a much stronger
interest in our blockbuster technology than ever before at Bio 2006,
which we think might confirm the analyst predictions that large-caps
need product. We also found a warm reception to explore in-licensing
opportunities to market and distribute niche products in Greece and
Eastern Europe. We are extremely pleased with the interest we have
garnered."

   Samaritan Pharmaceuticals: "We LIV....to Save Lives."

   Samaritan is a small-cap biotech, driven to discover, develop, and
commercialize, innovative therapeutics for AIDS, Alzheimer's, cancer
and heart disease. Look at www.samaritanpharma.com. Please register on
our Web site so we can notify you of upcoming conference calls, news
and events.

   Disclaimer

   The company disclaims any information that is created by an
outside party and endorses only information that is communicated by
its press releases, filings and Web site. This news release contains
forward-looking statements that reflect management's current beliefs
about the potential for its drug candidates, science and technology.
However, as with any biopharmaceutical under development, there are
significant risks and uncertainties in the process of development and
regulatory review. There are no guarantees that products will prove to
be commercially successful. For additional information about the
factors that affect the company's business, please read the company's
latest Form 10-K filed April 15, 2005. The company undertakes no duty
to update forward-looking statements.